Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq: EIGR) announced its participation in two upcoming investor conferences: the Stifel 2022 Healthcare Conference on November 15, 2022, at 10:55 a.m. ET, and the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 a.m. GMT. Both events will feature company presentations and one-on-one meetings. Live webcasts will be available on Eiger's website, with replays accessible for at least 90 days. Eiger specializes in innovative therapies for hepatitis delta virus (HDV) and has multiple programs designated as FDA Breakthrough Therapy.

PALO ALTO, Calif., Nov. 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management team will participate in the following upcoming investor conferences:

Stifel 2022 Healthcare Conference

• Date & Time: Tuesday, November 15, 2022 at 10:55 a.m. ET
• Format: Company presentation and one-on-one meetings

Jefferies London Healthcare Conference

• Date & Time: Wednesday, November 16, 2022 at 11:30 a.m. GMT
• Format: Company presentation and one-on-one meetings

A live webcast of each presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com. Replays will be available on the website for at least 90 days. 

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-investor-conferences-301672184.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals is traded under the stock symbol EIGR on Nasdaq.

When is Eiger participating in the Stifel 2022 Healthcare Conference?

Eiger will participate in the Stifel 2022 Healthcare Conference on November 15, 2022, at 10:55 a.m. ET.

What date will Eiger present at the Jefferies London Healthcare Conference?

Eiger will present at the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 a.m. GMT.

Where can I find the live webcast of Eiger's presentations?

Live webcasts of Eiger's presentations will be available on the Investors section of their website at www.eigerbio.com.

What are the key therapeutic areas Eiger focuses on?

Eiger focuses on developing therapies for hepatitis delta virus (HDV) and other serious diseases.